Viridian COO amends Form 4 tax share withholding

Viridian Therapeutics Chief Operating Officer Thomas W. Beetham filed an amended insider report updating a prior Form 4.

Accepted by SEC EDGAR 03/09/2026 - 07:42 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Viridian Therapeutics Chief Operating Officer Thomas W. Beetham filed an amended insider report updating a prior Form 4. The amendment corrects the number of shares and price involved in a tax-withholding disposition of 3,048 shares of common stock at $30.19 per share on a transaction coded “F.”

These shares were withheld to cover taxes, rather than sold in an open-market trade. After this correction and all transactions reported in the original Form 4, Beetham is shown as beneficially owning 13,361 shares of Viridian Therapeutics common stock directly.

Insider Trade Summary

Exercise Price or Tax Liability: 3,048 shares

Exercise Price or Tax Liability 1 txn

Insider Beetham Thomas W.

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,048	$30.19	$92K

Holdings After Transaction: Common Stock — 13,361 shares (Direct)

Holdings Before and After: Common Stock, 16,409 to 13,361 shares (Direct)

Footnotes (1)

1. F1. This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Viridian Therapeutics (VRDN) report for Thomas W. Beetham?

Viridian Therapeutics reported that COO Thomas W. Beetham had 3,048 shares of common stock withheld at $30.19 per share to cover taxes. This was recorded as a tax-withholding disposition rather than an open-market sale and updated a previously filed Form 4.

Why was a Form 4/A amendment filed for Viridian Therapeutics (VRDN)?

The Form 4/A amendment was filed to correct the number of shares and the price reported as sold to cover taxes on the initial Form 4. It also corrected the resulting total number of shares Beetham beneficially owned after all transactions in that original filing.

How many Viridian Therapeutics (VRDN) shares were involved in the tax-withholding transaction?

The amended filing shows that 3,048 shares of Viridian Therapeutics common stock were used in a tax-withholding disposition. These shares were applied to satisfy tax obligations associated with equity compensation, rather than being sold through an open-market transaction or discretionary trade.

What is Thomas W. Beetham’s Viridian Therapeutics (VRDN) share ownership after the corrected transactions?

After the corrected transactions, Thomas W. Beetham is reported as beneficially owning 13,361 shares of Viridian Therapeutics common stock. This total reflects adjustments made in the amendment to fix earlier errors in the share count and transaction price disclosed on the initial Form 4.

How is the Viridian Therapeutics (VRDN) transaction coded on the Form 4/A?

The Viridian Therapeutics transaction is coded “F,” indicating a tax-withholding disposition where shares are delivered to cover tax liabilities. This code clarifies that the 3,048 shares were not part of a standard buy-or-sell trade but were used specifically for tax payment purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beetham Thomas W.

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		F		3,048(1)	D	$30.19	13,361(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

	/s/Jennifer Tousignant, Attorney-in-fact	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.